IMGN-779 is the interesting clinical option within the blood cancer landscape. This novel unmodified immunoglobulin selectively recognizes CD33, a protein present in a significant portion of acute myeloid leukemia. https://www.targetmol.com/compound/anti_cd33_antibody__imgn_779_naked_antibody_